Article citationsMore>>

Pistorius, M.A., Planchon, B., Schott, J.J. and Lemarec, H. (2006) Aspects héréditaires et génétiques de la maladie de Raynaud. Journal des Maladies Vasculaires, 31, 10-15.
https://doi.org/10.1016/s0398-0499(06)76512-x

has been cited by the following article:

• TITLE: Primary Raynaud’s Syndrome: An Intrinsic Autoimmune Disease that Is Amenable to Mycophenolate Mofetil

  AUTHORS: Kamel El-Reshaid, Shaima Al-Bader

  KEYWORDS: Raynaud’s Syndrome, Mycophenolate Mofetil, Treatment, Autoimmune, Idiopathic

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.13 No.11, November 21, 2024

  ABSTRACT: Raynaud’s syndrome (RS) is a vasospastic disorder with potential hereditary predisposition and multiple triggering factors. After the exclusion of external stimuli and local disorders, autoimmunity presents a potential intrinsic trigger even in idiopathic RS. We present a 47-year-old woman with severe and progressive RS in both hands and toes for 2 years. She did not have: a) clinical and laboratory evidence of systemic autoimmune diseases; b) prior drug exposure; c) local digits disease. She could not tolerate vasodilators. Since she had elevated C-reactive protein, she received MMF as immunosuppressive therapy. Within 2 weeks, her symptoms improved, and she remained disease-free for 2 years. In conclusion, blocking intrinsic autoimmune triggers with MMF is a safe, practical, and effective short- and long-term treatment for refractory primary RS.